ESMO 2019

Liquid biopsy and tumor tissue assays for comprehensive genomic profiling, surveillance & monitoring.  AVENIO NGS assays are for Research Use Only. Not for Use in Diagnostic Procedures.

*Research Use Only. Not for use in diagnostic procedures.

The only FDA-approved diagnostic test for NSCLC using liquid biopsy. Companion diagnostic for Tarceva^® (erlotinib), IRESSA^® (gefitinib) & TAGRISSO^® (osimertinib)

In collaboration with leading pharmaceutical companies, we identify and develop innovative predictive diagnostics to target those patients who are more likely to respond to specific therapies.

The global partner of choice for companion diagnostics, we help to advance Personalized Healthcare by delivering diagnostic confidence through a broad menu of high medical value predictive assays. Our standardized, fully-automated and easy-to-use solutions enable rapid turnaround time, empowering physicians to make the right patient decisions more quickly.

The Roche Digital Pathology solution combines innovative hardware, software and VENTANA Companion Algorithm image analysis software, and works in integrated harmony with the full Roche diagnostic portfolio for an end-to-end experience.

A clinical NGS reporting solution that can help labs accurately and efficiently interpret the clinical significance of mutations, empowering clinicians to deliver more personalized healthcare.

^**Not yet commercially available in the US

Developed as a result of the collaboration between Roche and GE Healthcare, NAVIFY Tumor Board is a cloud-based workflow product that securely integrates and displays relevant aggregated data into a single, holistic patient dashboard for oncology care teams to review, align and decide on the optimal treatment for the patient.

Optimized with new oligo probes, the VENTANA HER2 Dual ISH assay delivers clear, confident reads.

The new VENTANA HER2 Dual ISH DNA Probe Cocktail assay is a fully automated, ready-to-use brightfield solution for determining HER2 gene status. VENTANA HER2 Dual ISH helps identify breast and gastric cancer patients eligible for treatment with HER2-targeted personalized therapies.

The new VENTANA ROS1 assay is the first IVD IHC ROS1 test on the market. This pre-optimized, ready-to-use assay is highly correlated to FISH break-apart status, giving pathologists greater confidence when sending cases out for confirmatory testing. Guidelines from the College of American Pathologists and the National Comprehensive Cancer Network recommend ROS1 testing for confirmed lung adenocarcinoma cases.